0000000001087639

AUTHOR

J Farrell

showing 2 related works from this author

Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

2020

Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 1…

0301 basic medicineSYMPTOMSSmart phoneAllergyEscala visual analógicaINNOVATION[SDV]Life Sciences [q-bio]Medical and Health SciencesCorrelationvisual analogue scale0302 clinical medicineQuality of lifeVisual analogue scaleQUALITY-OF-LIFEMàscaresImmunology and AllergyscoreNoseRinitisRhinitisPRODUCTIVITY COSTSasthma; MASK; rhinitis; score; visual analogue scaleScoreExplained variationResponse VariabilityMobile ApplicationsALLERGIC RHINITISrhinitimedicine.anatomical_structureTRIALSRinite1107 Immunology[SDV.IMM]Life Sciences [q-bio]/ImmunologySmartphonemedicine.medical_specialtyMASKVisual analogue scaleMASK study groupImmunologyMACVIA-ARIA03 medical and health sciencesAllergicrhinitismedicineHumansvisual analogue scale.TECHNOLOGYIMMUNOTHERAPYAsmaAsthmabusiness.industryasthma; MASK; rhinitis; score; visual analogue scale; Humans; Smartphone; Asthma; Mobile Applications; Rhinitis; Rhinitis Allergicasthmamedicine.diseaseRhinitis AllergicAsthmaRHINOCONJUNCTIVITIS030104 developmental biology030228 respiratory system3121 General medicine internal medicine and other clinical medicinePhysical therapyClinical Medicinebusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.

2015

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive on…

Blood GlucoseCounselingMaleType 2 diabeteslaw.inventionBody Mass IndexRandomized controlled trialWeight losslawGlucagon-Like Peptide 1Weight managementSubcutaneousMedicine (all)ReducingNauseaGeneral MedicineMiddle AgedCombined Modality Therapy3. Good healthFemaletype 2 diabetesmedicine.symptomHumanmedicine.drugAdultDiarrheamedicine.medical_specialtyDiet ReducingInjections SubcutaneousInjections SubcutaneouPlaceboInjectionsDouble-Blind MethodInternal medicineWeight LossmedicineHumansHypoglycemic AgentsObesityExerciseHypoglycemic AgentLiraglutidebusiness.industryLiraglutidemedicine.diseaseWeight LoDietEndocrinologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and NutritionBody mass index[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyDyslipidemiaAdult; Blood Glucose; Body Mass Index; Combined Modality Therapy; Counseling; Diarrhea; Diet Reducing; Double-Blind Method; Exercise; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Injections Subcutaneous; Liraglutide; Male; Middle Aged; Nausea; Obesity; Weight Loss; Medicine (all)The New England journal of medicine
researchProduct